Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Interim results from two phase 1 trials demonstrate progress in the use of chimeric antigen receptor (CAR) T cell therapy for recurrent glioblastoma (GBM).
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1126/scitranslmed.adp2660 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Fourteen ways to make B cells the most interesting target in systemic lupus erythematosus].
Rev Med Interne
September 2025
Aix-Marseille Univ, C2VN, Inserm, INRAE, centre de néphrologie et transplantation rénale, CHU Conception, AP-HM, Marseille, France.
Evaluation of an Anti-thyroid Mode of Action for Thyroid Follicular Cell Adenomas in Female Mice Exposed to Tertiary Butyl Alcohol.
Regul Toxicol Pharmacol
September 2025
ToxStrategies LLC Katy, TX.
Chronic exposure to tertiary butyl alcohol (TBA) in drinking water (DW) is associated with low but increased incidence (15% vs 3% in controls) of thyroid follicular cell adenomas in female mice. The U.S.
View Article and Find Full Text PDFMathematical model suggests current CAR-macrophage dosage is efficient to low pre-infusion tumour burden but refractory to high tumour burden.
J Theor Biol
September 2025
Guangdong Immune Cell Therapy Engineering and Technology Research Center, Center for Protein and Cell-Based Drugs, Institute of Biomedicine and Biotechnology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China. Electronic address:
Chimeric antigen receptor (CAR)-macrophage therapy is a promising approach for tumour treatment due to antigen-specific phagocytosis and tumour clearance. However, the precise impact of tumour burden, dose and dosing regimens on therapeutic outcomes remains poorly understood. We developed ordinary differential equation (ODE) mathematical modelling and utilised parameter inference to analyse in vitro FACS-based phagocytosis assay data testing CD19-positive Raji tumour cell against CAR-macrophage, and revealed that phagocytosing efficiency of CAR-macrophage increases but saturates as both Raji cell and CAR-macrophage concentrations increase.
View Article and Find Full Text PDFAdvancement of clinical practice in delivering CAR T-cell therapy: impact on healthcare resource utilization and comparison with autologous stem cell transplantation in patients with relapsed/refractory large B-cell lymphomas.
Ann Hematol
September 2025
Institute for Workflow-Management in Health Care, European University of Applied Sciences, Cologne, Germany.
In patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) who are either refractory to first-line therapy or relapse within 12 months, chimeric antigen receptor (CAR) T-cell therapy is more effective than salvage chemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation (ASCT) as second-line therapy. Adoption of CAR T-cell therapy into routine clinical practice involves a period of adaptation and refinement of clinical processes. We aimed to document the evolution of clinical processes for CAR T-cell therapy during 2022 and 2023, and compare healthcare resource utilization (HCRU) associated with CAR T-cell and ASCT processes in routine clinical practice.
View Article and Find Full Text PDFIntegration of humanized ROBO1 CAR in PD-1 locus in natural killer cells delivers synergistic tumor-killing effect against non-small cell lung cancer.
Cancer Gene Ther
September 2025
Department of Physiology, Xiangya School of Basic Medical Science, Central South University, Changsha, Hunan, China.
Lung cancer is the most common cancer and one of the leading causes of cancer-related deaths in the world, however, the treatment of non-small cell lung cancer (NSCLC) is still limited, and it is a clinically urgent problem. ROBO1 is an important surface receptor on tumor cells, but the role of humanized chimeric antigen receptor (CAR) modified natural killer (NK) cells targeting ROBO1 in NSCLC is rarely explored. Furthermore, the role of PD-1 in NK cell killing tumor cells remains controversial.
View Article and Find Full Text PDF